Development of Thermosensitive Mucoadhesive Gel Based Encapsulated Lipid Microspheres as Nose-to-Brain Rivastigmine Delivery System DOI

Nurafni Annisa Achmad,

Rachmatya W. Tuna,

Irfan Kurniawan

et al.

Langmuir, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 23, 2024

Alzheimer's disease (ALZ) is a neurodegenerative that damages neuronal cells and causes decline in cognitive abilities. Administration of cholinesterase inhibitor compounds the primary choice treatment ALZ, one which rivastigmine (RVT). Several routes administration RVT are available, such as oral transdermal. However, route, has low bioavailability, undergoes first-pass metabolism, presence blood-brain barrier (BBB) reduces therapeutic concentration RVT. The transdermal route nonselective target brain. This study aims to combine thermosensitive mucoadhesive gel (TG) lipid microspheres (LM) drug delivery system improve efficacy Combining these will prevent systemic side effects increase LM was formulated with varying concentrations Compritol polymer. results evaluation showed values particle size, PDI, %EE %DL were 8.519 μm, 0.018 ± 0.004, 72.54%, 76.43%, respectively. TG formulation can provide liquid form at room temperature (25 °C) nasal (35 °C). Hemolytic HET-CAM tests confirmed LM's safety for use.

Language: Английский

Development of Thermosensitive Mucoadhesive Gel Based Encapsulated Lipid Microspheres as Nose-to-Brain Rivastigmine Delivery System DOI

Nurafni Annisa Achmad,

Rachmatya W. Tuna,

Irfan Kurniawan

et al.

Langmuir, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 23, 2024

Alzheimer's disease (ALZ) is a neurodegenerative that damages neuronal cells and causes decline in cognitive abilities. Administration of cholinesterase inhibitor compounds the primary choice treatment ALZ, one which rivastigmine (RVT). Several routes administration RVT are available, such as oral transdermal. However, route, has low bioavailability, undergoes first-pass metabolism, presence blood-brain barrier (BBB) reduces therapeutic concentration RVT. The transdermal route nonselective target brain. This study aims to combine thermosensitive mucoadhesive gel (TG) lipid microspheres (LM) drug delivery system improve efficacy Combining these will prevent systemic side effects increase LM was formulated with varying concentrations Compritol polymer. results evaluation showed values particle size, PDI, %EE %DL were 8.519 μm, 0.018 ± 0.004, 72.54%, 76.43%, respectively. TG formulation can provide liquid form at room temperature (25 °C) nasal (35 °C). Hemolytic HET-CAM tests confirmed LM's safety for use.

Language: Английский

Citations

0